Genes and environment: Novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 1961-1969

  Mbewe Campbell, Nzali ^a   Wei, Zhiyun ^a   Zhang, Kuixing ^a   Friese, Ryan S ^a   Mahata, Manjula ^a   Schork, Andrew J ^a   Rao, Fangwen ^a   Chiron, Stephane ^a   Biswas, Nilima ^a   Kim, Hyung Suk ^b   Mahata, Sushil K ^a   Waalen, Jill ^c   Nievergelt, Caroline M ^d   Hook, Vivian Y ^e   O'Connor, Daniel T ^a,f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Department of Psychiatry ^*  (United States)

^e Skaggs School of Pharmacy   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

autonomic; genetics; hypertension; nervous system

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CATHEPSIN L; DIOXIN;

ALLELE; ARTICLE; BLOOD PRESSURE; CHROMAFFIN CELL; DIASTOLIC BLOOD PRESSURE; DIPLOIDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; XENOBIOTIC RESPONSE ELEMENT;

EID: 84866554963     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328356b86a     Document Type: Article

References (25)

1. Funkelstein L, Toneff T, Hwang SR, Reinheckel T, Peters C, Hook V. Cathepsin L participates in the production of neuropeptide Y in secretory vesicles, demonstrated by protease gene knockout and expression. J Neurochem 2008; 106:384-391.
2. Biswas N, Rodriguez-Flores JL, Courel M, Gayen JR, Vaingankar SM, Mahata M, et al. Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology 2009; 150:3547-3557.
3. Stypmann J, Glaser K, Roth W, Tobin DJ, Petermann I, Matthias R, et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A 2002; 99:6234-6239.
4. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. Cathepsin L deficiency as molecular defect of furless: Hyper-proliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 2000; 14:2075-2086.
5. WenG, Mahata SK, CadmanP, MahataM, GhoshS, Mahapatra NR, etal. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 2004; 74:197-207.
6. Rozen S, Skaletsky H. Primer3 on the www for general users and for biologist programmers. Methods Mol Biol 2000; 132:365-386.
7. Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, et al. Population-based sample reveals gene-gender interactions in blood pressure in white Americans. Hypertension 2007; 49:96-106.
8. Schork NJ, Nath SK, Fallin D, Chakravarti A. Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjects. Am J Hum Genet 2000; 67:1208-1218.
9. Tenesa A, Visscher PM, Carothers AD, Knott SA. Mapping quantitative trait loci using linkage disequilibrium: Marker-versus trait-based methods. Behav Genet 2005; 35:219-228.
10. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41:207-210.
11. Jideus L, Ericson M, Stridsberg M, Nilsson L, Blomstrom P, Blomstrom-Lundqvist C. Diminished circadian variation in heart rate variability before surgery in patients developing postoperative atrial fibrillation. Scand Cardiovasc J 2001; 35:238-244.
12. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
13. Thompson JD, Higgins DG, Gibson TJ. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.
14. Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 2004; 5:276-287.
15. D'Agostino RBJSr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 2008; 117:743-753.
16. Probst MR, Reisz-Porszasz S, Agbunag RV, Ong MS, Hankinson O. Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. Mol Pharmacol 1993; 44:511-518.
17. Lattanzi W, Bernardini C, Gangitano C, Michetti F. Hypoxia-like tran-scriptional activation in tmt-induced degeneration: Microarray expression analysis on PC12 cells. J Neurochem 2007; 100:1688-1702.
18. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA, Thompson LM. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet 2005; 14:1529-1538.
19. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 2006; 15:273-285.
20. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, et al. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell 2004; 119:1041-1054.
21. Medicine, Institute of. Veterans and agent orange: Update 2006. Institute of Medicine. 2007.
22. Lund AK, Agbor LN, Zhang N, Baker A, Zhao H, Fink GD, et al. Loss of the aryl hydrocarbon receptor induces hypoxemia, endothelin-1, and systemic hypertension at modest altitude. Hypertension 2008; 51:803-809.
23. Woon PY, Kaisaki PJ, Braganca J, Bihoreau MT, Levy JC, Farrall M, Gauguier D. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A 2007; 104:14412-14417.
24. Pia Monica Lind EI, Ann-Christine Syvänen, Lars Lind. A polymorphism in the AH-receptor gene is related to hypertension and endothelium-dependent vasodilation (abstract). Toxicol Lett 2009; 189:S100-S101.
25. Ehret GB, Munroe PB, Rice KM, Bochud VM, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478:103-109.